This study is currently not recruiting participants.

A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550mg TID in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D)

Investigation of Treatment for Digestive Condition with Diarrhea

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

This study is being conducted to help us learn more about how to help people who have Irritable Bowel Syndrome with diarrhea.

Detailed description of study

This study is being conducted to help us learn more about how to help people who have Irritable Bowel Syndrome with diarrhea.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Irritable Bowel Syndrome
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the treatment of Irritable Bowel Syndrome (IBS) with diarrhea. IBS is a condition that affects the digestive system, causing symptoms like stomach cramps, bloating, and diarrhea. The study aims to understand better how an investigational medication may help manage these symptoms.

Participants in this study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will compare the effects of the investigational medication and the placebo to determine its effectiveness.

  • Who can participate: Participants must be adults aged 18 to 65 years with a diagnosis of IBS with diarrhea. Key eligibility factors include experiencing frequent diarrhea and abdominal discomfort.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo.
Updated on 19 Feb 2024. Study ID: 1208009288

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team